Shire sells cancer drugs to Servier for $2.4bn as Takeda circles
Divestment of the cancer business may be a deterrent for Takeda
Japanese drug kingpin Takeda mulling approach for Shire
Any deal would likely bid Irish rare disease specialist at close to €57bn
Pharma group Shire signs training deal for Dublin
Irish domiciled company to get ‘customised training programmes’ from universities
Dublin-based Shire Pharmaceuticals sees earnings rise 14%
Firm planning to create 150 new jobs in State reports product sales up 110% to $3.4bn
Shire receives planning permission for Co Meath plant
Dublin-headquartered pharma giant is creating 400 jobs as part of the investment
Shire shares surge as drug group upgrades earnings guidance
Irish-domiciled business says cost savings in $32bn Baxalta deal 40% more than expected
Perils of paying CEOs too much: When shareholders say no
Shareholders are rejecting proposals to ramp up CEOs’ rewards
Pharma group Shire to create 400 jobs in Co Meath
Republic a ‘strategically important location’ for the company
Cantillon: Shire takeover of Baxalta fails to impress shareholders
Shire shares slide 8% as analysts concerned about ambitious savings target from merger
Shire to buy Dyax for $5.9 bn
Deal will give Dublin-based pharma group access to treatment for inflammatory disease
Shire results beat forecasts as it still tracks Baxalta
CEO Flemming Ornskov refused to be drawn on whether drugmaker will pitch new higher offer
Shire seeks access to $30bn takeover target Baxalta’s books
Shire CEO confident Baxalta shareholders are open to a deal
Shire seen having to raise $30bn Baxalta bid
Investor says shareholders in Dublin company may back increase from current $45.23 a share offer to $50 but some unease over scale of acquisition
Shire beats analysts’ forecasts with first-quarter earnings
Dublin-based company wins more sales for drugs treating ADHD
Shire structure puts spotlight on tax
Drug firm has come out fighting after allegations it engaged in tax avoidance on an industrial scale
Dublin-headquartered Shire faces fresh scrutiny over tax
Questions on firm’s $1.6 billion “break fee” from AbbVie
Patent win helps Shire as AbbVie plots next bid move
London-listed pharma company has already spurned a $46 billion takover offer from US firm
Shire worth more than Abbvie bid, says CEO
Product sales will increase at a double-digit rate with expansion in drugs for rare diseases
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices